AstraZeneca (AZNCF) News Today $157.09 -0.71 (-0.45%) As of 08/22/2025 03:11 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartDividendFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock AZNCF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period AstraZeneca’s New Asthma Study: Potential Market ImpactAugust 22 at 7:51 PM | msn.comAstraZeneca’s Innovative Lung Cancer Screening Study: A Game Changer for Early DetectionAugust 22 at 7:51 PM | msn.comAstraZeneca (LSE:AZN) Joins Forces To Launch Sovereign AI Supercomputer With Sferical AIAugust 22 at 2:49 PM | finance.yahoo.comAstraZeneca Vietnam office in Hanoi receives LEED Gold certificationAugust 22 at 9:48 AM | msn.comAstraZeneca PLC (OTCMKTS:AZNCF) Short Interest UpdateAugust 22 at 2:31 AM | americanbankingnews.comPEZA, AstraZeneca partner to boost pharma investments in PHAugust 21 at 9:50 AM | msn.comDTI, AstraZeneca to develop Pharma Innovation HubAugust 20 at 6:49 PM | msn.comAstraZeneca to build Philippines’ first pharma innovation hubAugust 19, 2025 | msn.comScared of needles? AstraZeneca launches FluMist Home nasal spray deliveryAugust 17, 2025 | msn.comAstraZeneca’s Anifrolumab Pregnancy Study: A New Chapter in SLE TreatmentAugust 16, 2025 | theglobeandmail.comAstraZeneca’s CAR-T Therapy Study: A New Hope for Hepatocellular CarcinomaAugust 16, 2025 | msn.comAstraZeneca launches at-home FluMist nasal spray deliveryAugust 15, 2025 | abcnews.go.comAmgen and AstraZeneca’s New Study on Tarlatamab for Lung Cancer: Key Insights for InvestorsAugust 15, 2025 | theglobeandmail.comAstraZeneca’s CRT Study in Russia: Implications for Lung Cancer TreatmentAugust 13, 2025 | msn.comSolid Earnings Reflect AstraZeneca's (LON:AZN) Strength As A BusinessAugust 9, 2025 | finance.yahoo.comBritain is squeezing AstraZeneca too tightAugust 8, 2025 | ft.comAstraZeneca’s Phase 1 Study on AZD9833: A New Hope for Advanced Breast CancerAugust 8, 2025 | msn.comInside AstraZeneca’s long-game strategy in lung cancerAugust 7, 2025 | finance.yahoo.comAstraZeneca’s New Trial: A Potential Breakthrough for Eosinophilic Diseases in ChildrenAugust 7, 2025 | msn.comAstraZeneca slips Wednesday, underperforms marketAugust 6, 2025 | marketwatch.comAstraZeneca’s New Study on Trastuzumab Deruxtecan: A Potential Game-Changer in Cancer TreatmentAugust 6, 2025 | msn.comUBS Reaffirms Their Buy Rating on AstraZeneca (AZN)August 6, 2025 | theglobeandmail.comAstraZeneca’s Innovative Propellant Study: Market Implications and Future ProspectsJuly 31, 2025 | msn.comAstraZeneca’s PHRASE-HF Study: A Game Changer in Heart Failure Treatment?July 31, 2025 | msn.comWhy AstraZeneca Stock Was Topping the Market on TuesdayJuly 30, 2025 | msn.comAstraZeneca Just Missed Estimates, but Here’s Why Bulls Aren’t Worried YetJuly 30, 2025 | msn.comStock Movers: AstraZeneca, Philips, StellantisJuly 29, 2025 | bloomberg.comAstraZeneca beats profit expectations on robust drug sales, U.S. demandJuly 29, 2025 | msn.comAstraZeneca seeks US drug price cuts amid expansion plans, strong demandJuly 29, 2025 | msn.comLONDON BRIEFING: AstraZeneca earnings increase; Greggs profit sinksJuly 29, 2025 | lse.co.ukAstraZeneca beats forecasts after record US growthJuly 29, 2025 | ft.comAstraZeneca trumps Q2 forecasts, keeps outlook amid pricing, trade pressuresJuly 29, 2025 | za.investing.comAstraZeneca Quarterly Net Profit Jumps On Record US GrowthJuly 29, 2025 | barrons.comAstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of GefurulimabJuly 29, 2025 | msn.comAstraZeneca second quarter sales and profit boosted by cancer drugsJuly 29, 2025 | lse.co.ukAstraZeneca Profit, Revenue Lifted by Cancer DrugsJuly 29, 2025 | bloomberg.comAstraZeneca's Imfinzi granted priority review for cancer forms in USJuly 28, 2025 | lse.co.ukAstraZeneca’s (AZN) Dividend: Resilient, Predictable, and Built on InnovationJuly 26, 2025 | msn.comAstraZeneca Expected to Post Higher Core EPS, Total Revenue -- Earnings PreviewJuly 25, 2025 | marketwatch.comAstraZeneca (LSE:AZN) Showcases Promising Results For Gefurulimab In Global Myasthenia Gravis StudyJuly 25, 2025 | finance.yahoo.comAstraZeneca's eco-friendly version of smoker's lung inhaler gets EU panel backingJuly 25, 2025 | reuters.comAstraZeneca to build its largest-ever manufacturing facility in Virginia, creating hundreds of jobsJuly 24, 2025 | msn.comAstraZeneca investing $50B in US, Trump calls it an ‘honor’July 24, 2025 | msn.comAstraZeneca’s MAGELLAN Study: A New Horizon in NSCLC TreatmentJuly 24, 2025 | msn.comgMG race hots up as AstraZeneca’s star candidate meets Phase III targetsJuly 24, 2025 | finance.yahoo.comAstraZeneca to spend $50 billion in US production build out to avert tariff threatJuly 24, 2025 | dallasnews.comDAstraZeneca rare disease antibody shy of main goal in trialJuly 16, 2025 | lse.co.ukAstraZeneca’s New Study Targets COPD Burden in Egypt: What Investors Need to KnowJuly 15, 2025 | msn.comAstraZeneca drug may lead to lower blood pressure, trial suggestsJuly 14, 2025 | lse.co.ukAstraZeneca shares gain after drug shows success in late-stage hypertension trialJuly 14, 2025 | in.investing.com Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZNCF and its competitors with MarketBeat's FREE daily newsletter. Email Address AZNCF Media Mentions By Week AZNCF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AZNCF News Sentiment▼0.020.66▲Average Medical News Sentiment AZNCF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AZNCF Articles This Week▼107▲AZNCF Articles Average Week Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZNCF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 4Front Ventures News Today Ainos News Today Algernon Pharmaceuticals News Today Allstar Health Brands News Today AVAX Technologies News Today BriaCell Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:AZNCF) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access